AGEN vs DERM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AGEN's deterministic health scores are severely compromised: a Piotroski F-Score of 0/9 signals extreme financial distress, and the absence of an Altman Z-Score with negative profitability and liquidity ratios indicates high bankruptcy risk. Despite a 20.4% YoY revenue growth and recent EPS improvement, the company remains unprofitable with a -32.92% profit margin and negative ROA. The stock trades at a price/sales of 1.35, but with no intrinsic value or Graham Number, it lacks a fundamental floor. Analysts' target price of $12.33 is not supported by current fundamentals, suggesting overvaluation based on speculative growth expectations.
DERM shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
AGEN vs DERM: Head-to-Head Comparison
This page compares Agenus Inc. (AGEN) and Journey Medical Corporation (DERM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.